Table 2.

Active clinical trials in tumors with CXCR1 and CXCR2 inhibitors

	ACTIVE CLINICAL TRIALS IN TUMORS
Target	inhibitor	Pathology	N° of trial	Phase
CXCR2	AZD5069 in combination with the androgen receptor antagonist, Enzalutamide	Metastatic Castration Resistant Prostate Cancer	NCT03177187	2
CXCR1/2	SX-682 in combination with the anti-PD-1, Nivolumab	RAS Mutated Microsatellite Stable Metastatic Colorectal Cancer	NCT04599140	2
CXCR1/2	SX-682 in combination with the anti-PD-1, Nivolumab	Metastatic Pancreatic Ductal Adenocarcinoma	NCT04477343	1
CXCR1/2	SX-682 in combination with the bifunctional fusion protein targeting TGF-β and PD-L1 (BinTrafusp Alfa or M7824) and with the cancer vaccine CV301 TRICOM targeting carcinoembryonic antigen (CEA) and mucin1 protein (MUC1)	Advanced Solid Tumors (STAT)	NCT04574583	2
CXCR1/2	SX-682 in combination with the anti-PD-1, Pembrolizumab	Metastatic Melanoma	NCT03161431	1
CXCR1/2	Navarixin in combination with the anti-PD-1, Pembrolizumab	Advanced/Metastatic Solid Tumors (Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer)	NCT03473925	2

(AZD5069) CXCR2 antagonis; (Navarixin) CXCR1/2 inhibitor; (Pembrolizumab) monoclonal antibody anti-PD1; (SX-682) CXCR1/2 inhibitor